GeneDx: The Growth Story Isn't Dead, It's Changing (Rating Upgrade)
Source: SeekingAlpha
2026-02-24 07:50:00 ET
Overview
My first look at GeneDx ( WGS ) was in December 2024. This is a company that deals in exome sequencing–with a focus on rare disease diagnosis. Back then, GeneDx was experiencing robust revenue growth–52% YoY–and operating leverage....
Read the full article on Seeking Alpha
For further details see:
GeneDx: The Growth Story Isn't Dead, It's Changing (Rating Upgrade)
GeneDx Holdings Corp.
NASDAQ: WGS
WGS Trading
5.88% G/L:
$85.34 Last:
489,787 Volume:
$84.29 Open:
WGS Latest News
March 09, 2026 08:30:00 am
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity(TM) and Real-World Genomic Leadership
February 26, 2026 05:00:14 pm
GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell?
WGS Stock Data
$2,739,577,040
20,348,831
0.11%
111
N/A
Medical Diagnostics & Screening
Healthcare
US
Stamford
